ABSTRACT

Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is predominantly an inherited cardiomyopathy with typical histopathological characteristics of fibro-fatty infiltration mainly involving the right ventricular (RV) inflow tract, RV outflow tract, and RV apex in the majority of patients. The above pathologic evolution frequently brings patients with ARVD/C to medical attention owing to the manifestation of syncope, sudden cardiac death (SCD), ventricular arrhythmogenesis, or heart failure. To prevent future or recurrent SCD, an implantable cardiac defibrillator (ICD) is highly desirable in patients with ARVD/C who had experienced unexplained syncope, hemodynamically intolerable ventricular tachycardia (VT), ventricular fibrillation, and/or aborted SCD. Notably, the management of frequent ventricular tachyarrhythmias in ARVD/C is challenging, and the use of antiarrhythmic drugs could be unsatisfactory or limited by the unfavorable side effects. Therefore, radiofrequency catheter ablation (RFCA) has been implemented to treat the drug-refractory VT in ARVD/C for decades. However, the initial understanding of the link between fibro-fatty pathogenesis and ventricular arrhythmogenesis in ARVD/C is scarce, the efficacy and prognosis of endocardial RFCA alone were limited and disappointing. The electrophysiologists had broken through this frontier after better illustration of epicardial substrates and broadly application of epicardial approaches in ARVD/C. In recent works of literature, the application of epicardial ablation also successfully results in higher procedural success and decreases VT recurrences in patients with ARVD/C who are refractory to the endocardial approach during long-term follow-up. In this article, we review the important evolution on the delineation of arrhythmogenic substrates, ablation strategies, and ablation outcome of VT in patients with ARVD/C.

Keywords: Arrhythmogenic right ventricular dysplasia-cardiomyopathy; Catheter ablation; Percutaneous epicardial mapping; Ventricular tachycardia
INTRODUCTION

Arrhythmic right ventricular dysplasia/cardiomyopathy (ARVD/C) has generally been considered an inherited cardiomyopathy, which was first described in 1965. The defective cell-to-cell adhesion, which was mainly caused by seven dominant gene mutations that encode desmosomal proteins, is believed to be responsible for the pathogenesis of ARVD/C. As a consequence, the inflow tract of right ventricle (RV), RV apex, and right ventricular outflow tract (RVOT) are predisposed to the loss of cardiomyocytes and the substitution of ventricular myocardium to fibro-fatty tissue, which usually extends from the epicardium toward the endocardium. The inhomogeneous fibro-fatty infiltration of myocardium could result in slow conduction and anisotropic electrical propagation that potentially contribute to the arrhythmogenic substrates for reentrant circuits in ARVD/C. Apart from the above, the posterior lateral portion of left ventricle (LV) could be involved in an estimated 10% of patients with ARVD/C, which is frequently seen at the late stage of clinical course.

Accompanying the histopathological changes, clinical manifestations of ARVD/C could vary from syncope, ventricular tachyarrhythmias, progressive heart failure (HF), and sudden cardiac death (SCD). Owing to the diverse phenotype, the 2010 modified task force criteria have been proposed to facilitate the diagnosis of ARVD/C. It is worth noting that ventricular arrhythmias (VAs) and the associated symptoms frequently bring patients with ARVD/C to medical attention, and an implantable cardiac defibrillator (ICD) implantation is highly desirable to prevent SCD or recurrent symptoms in patients with definite ARVD/C, especially among those with unexplained syncope, hemodynamically unstable ventricular tachycardia (VT), ventricular fibrillation (VF), and aborted SCD.

The clinical management of patients with ARVD/C aims at 1) reducing the mortality; 2) decreasing VT recurrences and/or ICD interventions (either appropriate or inappropriate); 3) preventing ventricular dysfunction and progressive HF; 4) improving symptoms and quality of life; and 5) increasing the functional capacity. To achieve these goals, multidisciplinary strategies, including restriction of intense exercise, antiarrhythmic drug therapies, and catheter ablation, are warranted. However, clinical hurdles persist for those with frequent drug-refractory ventricular tachyarrhythmias in ARVD/C. Amiodarone with and without beta-blockers have been considered to prevent the occurrences of ventricular tachyarrhythmias in patients with ARVD/C with nonuniform effectiveness. However, given the unsatisfactory efficacy and the potential adverse effects, clinical application of antiarrhythmic drugs in ARVD/C would be limited, especially for those with young age and high activity. Therefore, catheter ablation was implemented to treat the ventricular tachyarrhythmias in ARVD/C for decades. In the era of endocardial ablation, the catheter ablation was considered palliative treatment because of the high recurrences of ventricular tachyarrhythmia. The critical epicardial nidus of VT circuits in patients with ARVD/C explains the potential failure of conventional endocardial mapping and catheter ablation. The better understanding of the epicardial electro-pathologic substrates contributing to the ventricular arrhythmogenesis in patients with ARVD/C and the improvement of navigation mapping system enable the electrophysiologists to localize and target the critical VT isthmuses and yield higher procedural success and lower VT recurrences through the incorporation of endocardial and epicardial ablation. The above evolution enhances the promising effectiveness of catheter ablation to be the preferred strategies for ARVD/C patients with clinically-documented VTs.
DIAGNOSIS OF ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA/CARDIOMYOPATHY

The appropriate management of VT strongly relies on the clinician awareness and accurate diagnosis of ARVD/C. The International Task Force criteria for the diagnosis of ARVD/C was first proposed by McKenna et al. in 1994 and revised by Marcus et al. in 2010 through the incorporation of new knowledge and technology to improve the diagnostic sensitivity. Patients with suspicion or at-risk of ARVD/C should be evaluated by serial evaluations consisting of family history, electrocardiography (ECG), signal-averaged ECG, echocardiography and/or cardiac magnetic resonance imaging, Holter monitoring, and genetic analysis, and/or RV angiography, RV endomyocardial biopsy. In spite of the above information, distinguishing ARVD/C from other mimicking diseases, such as idiopathic RVOT VT, amyloidosis, myocarditis, sarcoidosis, or endomyocardial fibrosis, is sometimes challenging but of clinical importance in the viewpoint of ablation strategy and prognosis.

PATIENTS SELECTION FOR CATHETER ABLATION IN ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA/CARDIOMYOPATHY

VAs in patients with ARVD/C frequently bring to medical attention as the initial manifestation during the second to fifth decade of life. The clinical manifestations of VA can range from isolated premature ventricular complex (PVC), non-sustained or sustained VT, to fatal ventricular flutter (VFL) and VF. Although there were no randomized trials to demonstrate the benefit of an ICD implantation in patients with ARVD/C, observational studies have consistently shown the effect to prevent SCD, mostly driven from episodes of VF or hemodynamic intolerable sustained VT. Hitherto, the updated guideline recommended an ICD implantation for the patients with ARVD/C with documented sustained VT/VF or survivors experiencing aborted SCD provided the high recurrences of VA-associated mortality or morbidity. In spite of several risk factors have been identified, it remains controversial for those at-risk or without life-threatening VAs to receive an ICD implantation as primary prevention. Furthermore, beta-blocker and other anti-arrhythmic drugs are frequently limited by the intolerable adverse effect or the unsatisfactory effectiveness to avoid the recurrent episodes of VAs and ICD interventions. Given the advancement of ablation techniques and mapping system, there are growing shreds of evidence to demonstrate the role of catheter ablation in preventing the recurrent VTs in patients with ARVD/C. Previously, catheter ablation was only considered an alternative choice for drug-refractory VTs. Nevertheless, though there was no randomized trial to investigate the timing of VT ablation in ARVD/C, recent study demonstrated that early referral for VT ablation in structural heart diseases was associated with less VT recurrences and the occurrences of acute complications. Future works are needed to elucidate the role of ablation as the initial step once if patients with ARVD/C have documented VTs. Also, the benefits of ablation in ARVD/C patients with inducible VTs during invasive electrophysiologic studies without clinically-documented VTs or patients presenting with PVC or VF remain questionable.
ELECTROPHYSIOLOGICAL STUDY IN ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA/CARDIOMYOPATHY

First, the electrophysiological study could yield the valuable information to differentiate idiopathic RVOT VT from ARVD/C. The programmed electrical stimulation not only have a pivotal role to assess the vulnerability of ventricular tachyarrhythmias, but also provide clues for the diagnosis of ARVD/C. Denis et al. demonstrated that either the presence of polymorphic premature ventricular contractions with ≥1 couplet, sustained or non-sustained VT with left bundle branch block morphology after excluding RVOT VT by high dose isoproterenol (45 μg/min) infusion could help to diagnose ARVD/C in the early stage with a sensitivity of 91.4% and a specificity of 88.9%. Apart from the above, the role of inducible sustained VT or VF to predict future arrhythmic outcome remained unsolved. The multicenter studies demonstrated the limited value of programmed ventricular stimulation as a risk stratification strategy in patients with ARVD/C who carry the risk of fatal VA or cardiac arrest. Corrado et al. reported that the positive and negative predictive value of VT/VF inducibility for substantial outcome in patients with ARVD/C receiving an ICD implantation as primary prevention was 35% and 70%, respectively. The North American Multidisciplinary study also echoed the above findings that spontaneous VA before enrollment and a younger age of ICD implantation rather than the inducible VT/VF by programmed stimulation can predict the occurrence of life-threatening VT/VF in patients ARVD/C. However, Bhonsale et al. demonstrated that only positive inducibility and non-sustained VT could predict appropriate ICD therapy in patients with definite or probable ARVD/C receiving ICD implantation for primary preventions after multivariable analysis. The above conflicting findings may be caused by the heterogeneous study population, diverse disease spectrum, the different protocol of programmed stimulation, and the non-uniform endpoints.

Nowadays, catheter ablation is emerging as one of the therapeutic options to prevent VT recurrences in the patients with ARVD/C through the combination of endocardial and epicardial approaches. The understanding of the electrophysiologic characteristics and electroanatomic substrates responsible for the ventricular arrhythmogenesis was derived from the reports of international electrophysiologic laboratory over the world. The detailed electrophysiologic study during catheter ablation not only help understand the underlying characteristics, reproduce clinically-documented VT, but also help to assess the ablation outcome. Through these experiences, the mechanism of ventricular arrhythmogenesis and ablation strategies have been learned to facilitate successful catheter ablation and long-term freedom from VT recurrences.

CATHETER SELECTION FOR SUBSTRATE MAPPING

Some electrophysiologists use the traditional mapping catheters with a 3.5 mm distal tip electrode that is separated by 2 mm from a 2 mm proximal electrode for substrate mapping. Therefore, the bipolar electrogram only represents the underlying tissue diameter ranging from 3.5 to 7.5 mm. The newly developed multielectrode mapping catheters with ≤1 mm electrodes and shorter inter-electrode spacing can record the electrogram from a significantly smaller underlying tissue diameter ranging from 1 to 3 mm (also dependent on catheter orientation relative to the surface). The small electrodes and shorter inter-electrode spacing of multielectrode mapping catheter demonstrated the advantages of not only higher density but better resolution of the abnormal substrates, which could therefore facilitate to delineate the heterogeneous area of low voltage and to localize the potential channels compositing surviving myocardial bundles that might be
responsible for the development of VAs in ARVD/C (Figure 1). In spite of the better illustration of the abnormal electrograms, current automatic annotation criteria of the navigation system may not be precise enough, especially for fractionated low voltage signals in the scarred myocardium and manual adjustment and exclusion of noise and artifacts are frequently needed. The improvement of annotation algorithms will be highly desirable to overcome the current frontier.

**ENDOCARDIAL AND EPICARDIAL SUBSTRATE MAPPING IN ARVD/C**

Advances in 3-dimensional (3D) electroanatomic mapping fasten the electrophysiologists to understand the throughout substrate properties in patients with ARVD/C, which can be helpful to localize the VT origins. The distribution of electroanatomic scar in patients with
ARVD/C typically extends from the tricuspid annulus and RVOT toward the RV free wall and RV apex, which was known as the triangle of dysplasia (Figure 2) despite that the LV abnormalities surrounding the basal perivalvular area have been reported. The detailed assessment of substrates underlying these arrhythmogenic areas during sinus or paced rhythm by 3D-colored electroanatomic voltage mapping provides pivotal insights to localize the reentrant circuits and decide the ablation strategies.

In our laboratory, we defined the bipolar voltage <1.5 mV, prolonged electrogram duration, fractionated potentials, and isolated late potentials (LPs) as the abnormal substrates of RV endocardium, whilst the voltage threshold of 1.0 mV is used for the setting of epicardial bipolar voltage mapping. These abnormal low voltage areas were frequently correlated with the histopathologic findings of myocyte loss with fibrofatty replacement in patients with ARVD/C, whilst the distribution of abnormal electrograms is usually comparable to the VT reentrant circuits. Sometimes, the potential channels and VT isthmuses can be visualized through the adjustment of voltage limit within the widespread scar area. Noteworthy is that the thick epicardial fat layer surrounding atrioventricular/interventricular grooves or adjacent
to epicardial coronary vessels can result in epicardial bipolar low voltage area without the existence of abnormal fractionated or isolated electrograms.\textsuperscript{41} Imaging modalities such as cardiac computed tomography and magnetic resonance imaging can be integrated to the electroanatomic map to delineate these epicardial structures beyond the scar/low voltage zone. Operators should carefully review all the electrograms surrounding these epicardial vessels to prevent the overestimation of the low-voltage area or accidental vascular complication during ablation. The previous study based on contrast-enhanced magnetic resonance imaging also supported that the bipolar low voltage area and the territories displaying abnormal electrograms were correlated to the transmural scar.\textsuperscript{41,42}

In general, the disease process in ARVD/C initiates from the epicardium toward the endocardium. It is reasonable that the epicardial scar is larger than those within endocardium in ARVD/C (\textbf{Figure 2}). Though the endocardial substrate mapping is traditionally considered the first step, it is important to evaluate the estimated extent of RV epicardial substrates and clarify the benefit and necessity of epicardial approaches in patients with ARVD/C noninvasively. Moreover, the epicardial abnormal substrate is usually the target for successful VT ablation.\textsuperscript{43,44} However, elimination of epicardial circuit from endocardial ablation could be achieved in certain patients.\textsuperscript{45} Given the concern of safety and complications, an epicardial approach has been reserved for patients with failed endocardial ablation of VT in ARVD/C in certain electrophysiological laboratories.\textsuperscript{46} In the viewpoint of the above consideration, recognition of the potential epicardial substrates/circuits is of clinical significance.

First of all, the depolarization and repolarization manifestations of 12-lead ECG have been correlated with the substrate characteristics of ARVD/C in several studies. Tanawuttiwat et al.\textsuperscript{45} demonstrated that the presence of epsilon wave could be associated with severe conduction delay and the extensive endocardial scarring within the sub-tricuspid area based on the activation timing of epsilon wave. Tschabrunn et al.\textsuperscript{46} also reported the fragmentation of QRS in different territories provides information to localize the abnormal electroanatomic substrates and the origin of VAs. Furthermore, Kubala et al.\textsuperscript{47} demonstrated the area with abnormal electroanatomic mapping could be correlated to the extent of T wave inversion, while the down-sloping elevation of ST-segment in V\textsubscript{1} and V\textsubscript{2} was associated with larger abnormal endocardial unipolar voltage. The interelectrode dispersion of 12-leads ECG during sinus rhythm in ARVD/C reemphasized the importance of conduction heterogeneity in the contribution of depolarization abnormalities,\textsuperscript{48} whilst the Q wave or QS in regional leads during VAs may reflect the probable epicardial origin for RV VT.\textsuperscript{49} Second, unipolar voltage mapping of RV endocardium has been explored to predict the disease and the epicardial arrhythmogenic substrates.\textsuperscript{50} The RV endocardial voltage mapping not only illustrates the substrate characteristics but helps to evaluate the extent of epicardial abnormalities. Evaluation of the epicardial abnormal substrates can be achieved using the RV endocardial unipolar voltage mapping with a cutoff value of 5.5 mV, and the abnormal area is correlated to the epicardial scar in ARVD/C (\textbf{Figure 2}).\textsuperscript{51} though the different cut-off value of 4.4 mV has been proposed through the site-by-site comparison.\textsuperscript{50} Our group also found that the RV endocardial unipolar peak-negative voltage at a cut-off value of 1.66 mV is useful to predict the epicardial dense scar (<0.5 mV) in ARVD/C.\textsuperscript{51} Aside from the above, the discrepancy between endocardial and epicardial scar distribution was associated with the development of fatal VAs. In terms, the horizontal expansion rather than the transmural distribution of the substrates may result in the likelihood of electrical instability and predisposition to unstable ventricular tachyarrhythmias as the initial presentation.\textsuperscript{15} It is notably crucial to identify and annotate the location of fractionated signals, LPs, and/or high-frequency arrhythmogenic signals.
potentials which are potentially responsible for the VT isthmuses. Pacing maneuver or the novel simultaneous amplitude frequency electrogram transformation may facilitate the recognition of these arrhythmogenic potentials and elimination of these abnormal electrograms could potentially yield better prognosis.  

MAPPING OF VENTRICULAR TACHYCARDIA AND ABLATION STRATEGIES

The majority of VAs in ARVD/C is VT, though VF/VFL can still occur. Multiple monomorphic VTs in patients with ARVD/C were not rare, which therefore attract clinical electrophysiologists’ interests to eliminate these catastrophic events through catheter ablation. The VT induction in ARVD/C usually can be achieved by programmed ventricular stimulation with or without isoproterenol. Once if the VT is induced, the morphology should be compared to clinically-documented VT, if available, and/or the ICD electrograms recorded. Identification of the initiation and perpetuation of ventricular reentry is the primary objection during mapping of the VT isthmuses because the visualization and delineation of the critical components of the circuits can facilitate to effectively terminate the VTs through limited ablation. For hemodynamically-tolerable VT, the localization of the critical isthmuses relies on both activation and entrainment mapping. Pacing from the mapping catheter at a cycle-length of 20–30 msec faster than the tachycardia cycle length is needed when entrainment mapping was performed. The VT isthmuses are confirmed once the following criteria are achieved; 1) concealed fusion of all 12-lead ECG during entrainment, 2) the post-pacing interval within 30 msec of the VT cycle length, 3) the stimulus-to-electrogram interval was within 20 msec of the electrogram-QRS interval following entrainment, and 4) the local electrogram to QRS interval is between 30% and 70% of the VT cycle length. Notwithstanding the foregoing the above criteria, there are still several pitfalls during the entrainment pacing and accurate interpretation of the results could sometimes be challenging. Furthermore, recent findings from high-resolution mapping demonstrated that entrainment mapping may overestimate the lengths of VT isthmuses in a post-infarct experimental model. Therefore, high-density and high-resolution activation mapping by the acquisition of the earliest fractionated or splitting mid-diastolic potentials preceding QRS by at least more than 30 msec would be better to illustrate the VT isthmuses. Of interest, the endocardial electroanatomic activation mapping of VT frequently represents a centrifugal activation pattern with radial spreading. Usually, concealed entrainment could be achieved at the earliest activation site, implying the potential exit of the reentrant circuit. In patients with ARVD/C, the tricuspid annulus is frequently involved in the VT circuits. Therefore, the whole annulus should be mapped in detail. The application of long deflectable sheath is recommended to achieve the adequate contact and catheter stability. Nevertheless, unmappable VTs are frequently encountered in ARVD/C, mostly owing to the hemodynamically unstable condition, multiple reentrant circuits, or non-sustained VT. Though pace mapping in scar-related VT is less precise, pacing surrounding the dense scar border can help to identify the VT exit. Despite that only a minority of fractionated potentials may participate in the VT isthmuses, extensive substrates modification through local abnormal ventricular activities elimination, scar homogenization, scar dechanneling, or core isolation have been proved to decrease VT recurrences given the and was associated with better outcome. Given the potential fraught of voltage-based assessment, several different methods, such as fragmentation or frequency analysis
mapping, decrement evoked potentials mapping, ripple mapping, isochronal late activation mapping, or omnipolar mapping, have been proposed to assist in more effective and objective analysis of abnormal potentials or potential channels supporting VT isthmuses. Substrate modification relying on the integration of the above methods is usually the strategy of choice to achieve acute procedural success.

To date, radiofrequency is the most common energy source applying for VT ablation. A 3.5 or 4-mm irrigated-tip catheter is widely accepted to be more effective to create deeper lesions for intramural or epicardial circuits. In our laboratory, the power delivery is usually initiated at 30 W for the endocardial site and 20 W for epicardial site. The energy is titrated up to a maximum of 40 W for endocardium and 35 W for the epicardium while targeting an impedance drop of 10 Ω by maintaining for a minimum of 120 seconds to site of termination in stable VT or the disappearance of abnormal potentials at each point for substrate modification.

CONSIDERATION OF EPICARDIAL ABLATION

Though the percutaneous pericardial access was firstly introduced for epicardial VT ablation in Chagas disease in 1996, it has currently been applied to several different entities of diseases, such as ARVD/C, idiopathic dilated cardiomyopathy, ischemic cardiomyopathy with transmural scar, myocarditis, and Brugada syndrome. Epicardial approach has been proved to provide a better understanding of the arrhythmogenesis of abnormal substrates and ablation efficacy. However, the epicardial procedure still carries certain risks of catastrophic complications, such as coronary vessel injuries, major bleeding, delayed tamponade, or major pericardial reaction, even in the experienced and high-volume centers. Aside from the above, the presence of thick epicardial fat constraints the energy penetration to the protected isthmus and endocardial ablation has been reported to be able to eliminate the epicardial local abnormal ventricular activities in 73% of patients with ARVD/C (Figure 3). Therefore, the first-time application of epicardial procedure should be balanced between the benefits of procedural success and the risk of procedure-related cardiac or extra-cardiac complications.

OUTCOME OF VENTRICULAR TACHYCARDIA ABLATION IN ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA/CARDIOMYOPATHY

Most of the literatures reported the ablation outcome of ARVD/C from limited and nonuniform population, the different ablation strategies, distinct disease stages, and variable follow-up duration with heterogeneous results (Table 1). Initially, the long-term efficacy in prevention of VT recurrence could be achieved in only 25–53% of cases by endocardial ablation. The understanding of the underlying pathophysiology of ARVD/C and the application of epicardial ablation improved the unsatisfactory outcome. Recent studies demonstrated a significant benefit of freedom from VT recurrences or ICD therapy by 45–84.6% through the combination of endocardial and epicardial ablation. Again, the non-uniform ablation outcomes were likely caused by the mapping and ablation strategies, the variable endpoints, follow-up assessment, and operators’ experiences. Even though there has been a great improvement in ablation
techniques and clinical outcomes through epicardial ablation, clinical hurdles remain in the realm of managing patients after the failed epicardial ablation, patients with recurrences owing to rapid disease progression.

**CONCLUSION**

In summary, ARVD/C is predominantly an inherited progressive disease with fibrofatty infiltration and potentially the ventricular arrhythmogenesis. An early and accurate diagnosis relies on the detailed evaluation of cardiac imaging, ECG, histopathology, family history, genetic screening, and electrophysiological study in selected cases. Provided the better understanding of the pathogenesis, the underlying substrate properties, improvement of navigation mapping system, and widespread of epicardial approaches, ablation outcome
has been tremendously improved to reduce recurrent VT and ICD therapies, and therefore catheter ablation is emerging as a preferred therapeutic choice for VT in ARVD/C in well-developed electrophysiological laboratories. Further investigations are warranted to elucidate the role of catheter ablation as the first line therapy or primary ablation of VT in patients with ARVD/C, and the novel solution for those with failed endocardial/epicardial ablation or recurrent VT caused by rapid substrate evolution.

REFERENCES

1. Dalla Volta S, Fameli O, Maschio G. The clinical and hemodynamic syndrome of auricularisation of the right ventricle. (Apropos of 4 personal cases). Arch Mal Coeur Vaiss 1965;58:1129-43.
PUBMED

2. Basso C, Thieme G, Corrado D, et al. Arrhythmogenic right ventricular cardiomyopathy. Dysplasia, dystrophy, or myocarditis? Circulation 1996;94:983-91.
PUBMED | CROSSREF

3. Marcus FI, Fontaine GH, Guiraudon G, et al. Right ventricular dysplasia: a report of 24 adult cases. Circulation 1982;65:384-98.
PUBMED | CROSSREF

4. Hulot JS, Jouven X, Empana JP, et al. Natural history and risk stratification of arrhythmogenic right ventricular dysplasia/cardio myopathy. Circulation 2004;110:1879-84.
PUBMED | CROSSREF

5. Dalal D, Nasir K, Bomma C, et al. Arrhythmogenic right ventricular dysplasia: a United States experience. Circulation 2005;112:3823-32.
PUBMED | CROSSREF

6. Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Eur Heart J 2010;31:806-14.
PUBMED | CROSSREF

7. Corrado D, Wichter T, Link MS, et al. Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement. Circulation 2015;132:441-53.
PUBMED | CROSSREF

8. Maron BJ, Udelson JE, Bonow RO, et al. Eligibility and disqualification requirements for competitive athletes with cardiovascular abnormalities: task force 3: hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis: a scientific statement from the American Heart Association and American College of Cardiology. J Am Coll Cardiol 2015;66:2362-71.
PUBMED | CROSSREF

Table 1. Clinical outcome of VT ablation in ARVD/C

| Author            | Number of patients | Mapping strategies                  | Sites of targets | Acute results | Follow-up duration | Short-term freedom from VA recurrences (1 year) | Long-term freedom from VA recurrences |
|-------------------|--------------------|-------------------------------------|------------------|---------------|-------------------|------------------------------------------------|-------------------------------------|
| Dalal et al.      | 24                 | Conventional or 3D mapping          | Endocardial      | 46% for all inducible VT; 31% for clinical VT; 23% procedural failure | 32±36 months | 50% (5 months) | 25%                                               |
| Verma et al.      | 22                 | 3D mapping                          | Endocardial      | 82%           | 37 months (median) | 77% (1 years) | 53%                                               |
| Garcia et al.     | 13                 | 3D mapping                          | Endocardial+epicardial | 92% (for all targeted VT) | 18±13 months | -                                              | 77%                                               |
| Philips et al.    | 87                 | Conventional or 3D mapping          | Endocardial+epicardial | Complete success 47%; partial success 38%; procedural failure 15% | 88.3±66.1 months | 1 years: 47% (endocardial: 45%; epicardial 64%); 5 years: 21%; 10 years: 15% (5 years-endocardial 19%; 5 years-epicardial 45%) |
| Bai et al.        | 49                 | Conventional or 3D mapping          | Group 1: endocardium alone, (n=23); group 2: endo+epicardium (n=26) | Polymorphic VT/VF: 1 in group 1 and 2 in group 2 | At least 3 years group 1: 1,294±310 days; group 2: 1,175±112 days | 300 days follow-up group 1: 88.5%; group 2: 100%; 3-years follow-up group 1: 52.2%; group 2: 84.6% |
| Santangeli et al. | 62                 | 3D mapping                          | Endocardial+epicardial | VT non-inducibility: 71% | 56±44 months | -                                            | 71%                                               |
| Wei et al.        | 48                 | 3D mapping                          | Endocardial      | 81.3%         | 71.4±45.7 months | -                                              | 56.3%                                               |
| Lin et al.        | 80                 | 3D mapping                          | Endocardial+epicardial | 100%          | 38.11 months     | 95% (1 year) | 51.2%                                               |

3D = 3-dimensional; ARVD/C = arrhythmogenic right ventricular dysplasia/cardio myopathy; VA = ventricular arrhythmia; VF = ventricular fibrillation; VT = ventricular tachycardia.
9. Corrado D, Leoni L, Link MS, et al. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. *Circulation* 2003;108:3084-91.

10. Wichter T, Paul M, Wollmann C, et al. Implantable cardioverter/defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy: single-center experience of long-term follow-up and complications in 60 patients. *Circulation* 2004;109:1503-8.

11. Marechinski FE, Zado E, Dsik T, et al. Electroanatomic substrate and outcome of catheter ablative therapy for ventricular tachycardia in setting of right ventricular cardiomyopathy. *Circulation* 2004;109:2293-8.

12. Garcia FC, Bazan V, Zado ES, et al. Epicardial substrate and outcome with epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy/dysplasia. *Circulation* 2009;120:366-75.

13. Philips B, Madhavan S, James C, et al. Outcomes of catheter ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy. *Circ Arrhythm Electrophysiol* 2012;5:499-505.

14. Lin CY, Chung FP, Lin YJ, et al. Safety and efficacy of epicardial ablation of ventricular tachyarrhythmias: experience from a tertiary referral center in Taiwan. *Acta Cardiol Sin* 2018;34:49-58.

15. Lin CY, Lin YJ, Li CH, et al. Heterogeneous distribution of substrates between the endocardium and epicardium promotes ventricular fibrillation in arrhythmogenic right ventricular dysplasia/cardiomyopathy. *Europace* 2018;20:501-11.

16. Philips B, te Riele AS, Sawant A, et al. Outcomes and ventricular tachycardia recurrence characteristics after epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy. *Heart Rhythm* 2015;12:716-25.

17. Santangeli P, Zado ES, Supple GE, et al. Long-term outcome with catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular cardiomyopathy. *Circ Arrhythm Electrophysiol* 2015;8:1413-21.

18. McKenna WJ, Thiene G, Nava A, et al. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task force of the working group myocardial and pericardial disease of the European society of cardiology and of the scientific council on cardiomyopathies of the international society and federation of cardiology. *Br Heart J* 1994;71:215-8.

19. Avella A, d'Amati G, Pappalardo A, et al. Diagnostic value of endomyocardial biopsy guided by electroanatomic voltage mapping in arrhythmogenic right ventricular cardiomyopathy/dysplasia. *J Cardiovasc Electrophysiol* 2008;19:1127-34.

20. Chung FP, Lin YJ, Kuo L, et al. Catheter ablation of ventricular tachycardia/fibrillation in a patient with right ventricular amyloidosis with initial manifestations mimicking arrhythmogenic right ventricular dysplasia/cardiomyopathy. *Korean Circ J* 2017;47:282-5.

21. Philips B, Madhavan S, James CA, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy and cardiac sarcoidosis: distinguishing features when the diagnosis is unclear. *Circ Arrhythm Electrophysiol* 2014;7:230-6.

22. Groeneweg JA, Bhonsale A, James CA, et al. Clinical presentation, long-term follow-up, and outcomes of 1001 arrhythmogenic right ventricular dysplasia/cardiomyopathy patients and family members. *Circ Cardiovasc Genet* 2015;8:437-46.

23. Corrado D, Calkins H, Link MS, et al. Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia. *Circulation* 2010;122:1144-52.

24. Marcus FL, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. *Circulation* 2010;121:1533-41.
25. Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC) endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). *Europace* 2015;17:1601-87.

26. Romero J, Di Biase L, Diaz JC, et al. Early versus late referral for catheter ablation of ventricular tachycardia in patients with structural heart disease: a systematic review and meta-analysis of clinical outcomes. *JACC Clin Electrophysiol* 2018;4:374-82.

27. Do VB, Tsai WC, Lin YJ, et al. The Different substrate characteristics of arrhythmogenic triggers in idiopathic right ventricular outflow tract tachycardia and arrhythmogenic right ventricular dysplasia: new insight from noncontact mapping. *PLoS One* 2015;10:e0140167.

28. Denis A, Sacher F, Derval N, et al. Diagnostic value of isoproterenol testing in arrhythmogenic right ventricular cardiomyopathy. *Circ Arrhythm Electrophysiol* 2011;58:1485-96.

29. Bhonsale A, James CA, Tichnell C, et al. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. *J Am Coll Cardiol* 2011;64:119-25.

30. Saguner AM, Medeiros-Domingo A, Schwyzer MA, et al. Usefulness of inducible ventricular tachycardia to predict long-term adverse outcomes in arrhythmogenic right ventricular cardiomyopathy. *Am J Cardiol* 2013;111:250-7.

31. Link MS, Laidlaw D, Polonsky B, et al. Ventricular arrhythmias in the North American multidisciplinary study of ARVC: predictors, characteristics, and treatment. *J Am Coll Cardiol* 2014;64:119-25.

32. Bai R, Di Biase L, Shivkumar K, et al. Ablation of ventricular arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy: arrhythmia-free survival after endo-epicardial substrate based mapping and ablation. *Circ Arrhythm Electrophysiol* 2011;4:478-85.

33. Tschabrunn CM, Roujol S, Dorman NC, et al. High-resolution mapping of ventricular scar: comparison between single and multielectrode catheters. *Circ Arrhythm Electrophysiol* 2016;9:e003841.

34. Lin CY, Chung FP, Lin YJ, et al. Gender differences in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy: clinical manifestations, electrophysiological properties, substrate characteristics, and prognosis of radiofrequency catheter ablation. *Int J Cardiol* 2017;227:930-7.

35. Polin GM, Haqqani H, Tzou W, et al. Endocardial unipolar voltage mapping to identify epicardial substrate in arrhythmogenic right ventricular cardiomyopathy/dysplasia. *Heart Rhythm* 2011;8:76-83.

36. Cano O, Hutchinson M, Lin D, et al. Electroanatomic substrate and ablation outcome for suspected epicardial ventricular tachycardia in left ventricular nonischemic cardiomyopathy. *J Am Coll Cardiol* 2009;54:799-808.

37. Lin CY, Silberbauer I, Lin YJ, et al. Simultaneous amplitude frequency electrogram transformation (SAFE-T) mapping to identify ventricular tachycardia arrhythmogenic potentials in sinus rhythm. *JACC Clin Electrophysiol* 2016;2:459-70.
40. Arenal A, del Castillo S, Gonzalez-Torrecilla E, et al. Tachycardia-related channel in the scar tissue in patients with sustained monomorphic ventricular tachycardias: influence of the voltage scar definition. Circulation 2004;110:2568-74.

41. Venlet J, Piers SR, Kapel GF, et al. Unipolar endocardial voltage mapping in the right ventricle: optimal cutoff values correcting for computed tomography-derived epicardial fat thickness and their clinical value for substrate delineation. Circ Arrhythm Electrophysiol 2017;10:e005175.

42. Wijnmaalen AP, van der Geest RJ, van Huls van Taxis CF, et al. Head-to-head comparison of contrast-enhanced magnetic resonance imaging and electroanatomical voltage mapping to assess post-infarct scar characteristics in patients with ventricular tachycardias: real-time image integration and reversed registration. Eur Heart J 2011;32:104-14.

43. Haqqani HM, Tschabrunn CM, Betensky BP, et al. Layered activation of epicardial scar in arrhythmogenic right ventricular dysplasia: possible substrate for confined epicardial circuits. Circ Arrhythm Electrophysiol 2012;5:796-803.

44. Komatsu Y, Daly M, Sacher F, et al. Endocardial ablation to eliminate epicardial arrhythmia substrate in scar-related ventricular tachycardia. J Am Coll Cardiol 2014;63:1416-26.

45. Tanawuttiwat T, Te Riele AS, Philips B, et al. Electroanatomic correlates of depolarization abnormalities in arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Cardiovasc Electrophysiol 2016;27:443-52.

46. Tschabrunn CM, Haqqani HM, Santangeli P, et al. 12-lead electrocardiogram to localize region of abnormal electroanatomic substrate in arrhythmogenic right ventricular cardiomyopathy. JACC Clin Electrophysiol 2017;3:654-65.

47. Kubala M, Pathak RK, Xie S, et al. Electrocardiographic repolarization abnormalities and electroanatomic substrate in arrhythmogenic right ventricular cardiomyopathy. Circ Arrhythm Electrophysiol 2018;11:e005953.

48. Hsieh WH, Lin CY, Te AL, et al. A novel noninvasive surface ECG analysis using interlead QRS dispersion in arrhythmogenic right ventricular cardiomyopathy. PLoS One 2017;12:e0182364.

49. Jais P, Maury P, Khairy P, et al. Twelve-lead ECG features to identify ventricular tachycardia arising from the epicardial right ventricle. Heart Rhythm 2006;3:1132-9.

50. Tokuda M, Tedrow UB, Inada K, et al. Direct comparison of adjacent endocardial and epicardial electrograms: implications for substrate mapping. J Am Heart Assoc 2015;2:e000215.

51. Chi PC, Lin YJ, Chang SL, et al. Unipolar peak-negative voltage as an epicardial electrographic characteristic to predict overlying abnormal epicardial substrates in patients with right epicardial ventricular tachycardia. J Cardiovasc Electrophysiol 2014;25:1343-9.

52. Jais P, Maury P, Khairy P, et al. Elimination of local abnormal ventricular activities: a new end point for substrate modification in patients with scar-related ventricular tachycardia. Circulation 2012;125:2184-96.

53. Silberbauer J, Oloriz T, Maccabelli G, et al. Noninducibility and late potential abolition: a novel combined prognostic procedural end point for catheter ablation of postinfarction ventricular tachycardia. Circ Arrhythm Electrophysiol 2014;7:424-35.

54. Nogami A, Sugiyasu A, Tada H, et al. Changes in the isolated delayed component as an endpoint of catheter ablation of postinfarction ventricular tachycardia. Circ Arrhythm Electrophysiol 2008;19:681-8.

55. Ellison KE, Friedman PL, Ganz LI, et al. Entrainment mapping and radiofrequency catheter ablation of ventricular tachycardia in right ventricular dysplasia. J Am Coll Cardiol 1998;32:724-8.

56. Tung R. Challenges and pitfalls of entrainment mapping of ventricular tachycardia: ten illustrative concepts. Circ Arrhythm Electrophysiol 2017;10:e004560.
57. Anter E, Tschabrunn CM, Buxton AE, et al. High-resolution mapping of postinfarction reentrant ventricular tachycardia: electrophysiological characterization of the circuit. *Circulation* 2016;134:314-27.

58. Reithmann C, Hahnefeld A, Remp T, et al. Electroanatomic mapping of endocardial right ventricular activation as a guide for catheter ablation in patients with arrhythmogenic right ventricular dysplasia. *Pacing Clin Electrophysiol* 2003;26:1308-16.

59. de Chillou C, Groben L, Magnin-Poull I, et al. Localizing the critical isthmus of postinfarct ventricular tachycardia: the value of pace-mapping during sinus rhythm. *Heart Rhythm* 2014;11:175-81.

60. Nayyar S, Wilson L, Ganesan AN, et al. High-density mapping of ventricular scar: a comparison of ventricular tachycardia (VT) supporting channels with channels that do not support VT. *Circ Arrhythm Electrophysiol* 2014;7:90-8.

61. Di Biase L, Santangeli P, Burkhardt DJ, et al. Endo-epicardial homogenization of the scar versus limited substrate ablation for the treatment of electrical storms in patients with ischemic cardiomyopathy. *J Am Coll Cardiol* 2012;60:132-41.

62. Berruezo A, Fernández-Armenta J, Andreu D, et al. Scar dechanneling: new method for scar-related left ventricular tachycardia substrate ablation. *Circ Arrhythm Electrophysiol* 2015;8:326-36.

63. Tzou WS, Frankel DS, Hegeman T, et al. Core isolation of critical arrhythmia elements for treatment of multiple scar-based ventricular tachycardias. *Circ Arrhythm Electrophysiol* 2015;8:353-61.

64. Campos B, Jauregui ME, Marchlinski FE, et al. Use of a novel fragmentation map to identify the substrate for ventricular tachycardia in postinfarction cardiomyopathy. *Heart Rhythm* 2015;12:95-103.

65. Jackson N, Gizurarson S, Viswanathan K, et al. Decrement evoked potential mapping: basis of a mechanistic strategy for ventricular tachycardia ablation. *Circ Arrhythm Electrophysiol* 2015;8:1433-42.

66. Jamil-Copley S, Vergara P, Carbućchio C, et al. Application of ripple mapping to visualize slow conduction channels within the infarct-related left ventricular scar. *Circ Arrhythm Electrophysiol* 2015;8:76-86.

67. Luther V, Linton NW, Jamil-Copley S, et al. A prospective study of ripple mapping the post-infarct ventricular scar to guide substrate ablation for ventricular tachycardia. *Circ Arrhythm Electrophysiol* 2016;9:e004072.

68. Irie T, Yu R, Bradfield JS, et al. Relationship between sinus rhythm late activation zones and critical sites for scar-related ventricular tachycardia: systematic analysis of isochronal late activation mapping. *Circ Arrhythm Electrophysiol* 2015;8:390-9.

69. Aziz Z, Tung R. Novel mapping strategies for ventricular tachycardia ablation. *Curr Treat Options Cardiovasc Med* 2018;20:34.

70. d’Avila A, Houghtaling C, Gutierrez P, et al. Catheter ablation of ventricular epicardial tissue: a comparison of standard and cooled-tip radiofrequency energy. *Circulation* 2004;109:2363-9.

71. Sosa E, Scarnavacca M, d’Avila A, et al. A new technique to perform epicardial mapping in the electrophysiology laboratory. *J Cardiovasc Electrophysiol* 1996;7:531-6.

72. Maccabelli G, Tsiachris D, Silberbauer J, et al. Imaging and epicardial substrate ablation of ventricular tachycardia in patients late after myocardiitis. *Europace* 2014;16:1363-72.

73. Sosa E, Scarnavacca M, d’Avila A, et al. A new technique to perform epicardial mapping in the electrophysiology laboratory. *J Cardiovasc Electrophysiol* 1996;7:531-6.

74. Chung FP, Rahrarjo SB, Lin YJ, et al. A novel method to enhance phenotype, epicardial functional substrates, and ventricular tachyarrhythmias in Brugada syndrome. *Heart Rhythm* 2017;14:508-17.
75. Della Bella P, Brugada J, Zeppenfeld K, et al. Epicardial ablation for ventricular tachycardia: a European multicenter study. *Circ Arrhythm Electrophysiol* 2011;4:653-9.

76. Sosa E, Scanavacca M, d’Avila A, et al. Nonsurgical transthoracic epicardial catheter ablation to treat recurrent ventricular tachycardia occurring late after myocardial infarction. *J Am Coll Cardiol* 2000;35:1442-9.

77. Ozturk MT, Ebinç FA, Okyay GU, et al. Epicardial adiposity is associated with microalbuminuria in patients with essential hypertension. *Acta Cardiol Sin* 2017;33:74-80.

78. Aydin E, Altun C, Sakallioglu O, et al. Epicardial adipose tissue thickness and carotid intima-media thickness in hemodialysis patients. *Acta Cardiol Sin* 2017;33:266-72.

79. Ramazan Oncel C, Kucuk M. The value of epicardial adipose tissue thickness for cardiovascular risk stratification in hypertensive patients. *Acta Cardiol Sin* 2017;33:559.

80. Sacher F, Roberts-Thomson K, Maury P, et al. Epicardial ventricular tachycardia ablation a multicenter safety study. *J Am Coll Cardiol* 2010;55:2366-72.

81. Desjardins B, Morady F, Bogun F. Effect of epicardial fat on electroanatomical mapping and epicardial catheter ablation. *J Am Coll Cardiol* 2010;56:1320-7.

82. van Huls van Taxis CF, Wijnmaalen AP, Piers SR, et al. Real-time integration of MDCT-derived coronary anatomy and epicardial fat: impact on epicardial electroanatomical mapping and ablation for ventricular arrhythmias. *JACC Cardiovasc Imaging* 2013;6:42-52.

83. Sosa E, Scanavacca M. Epicardial mapping and ablation techniques to control ventricular tachycardia. *J Cardiovasc Electrophysiol* 2005;16:449-52.

84. Bai R, Patel D, Di Biase L, et al. Phrenic nerve injury after catheter ablation: should we worry about this complication? *J Cardiovasc Electrophysiol* 2006;17:944-8.

85. Roberts-Thomson KC, Steven D, Seiler J, et al. Coronary artery injury due to catheter ablation in adults: presentations and outcomes. *Circulation* 2009;120:1465-73.

86. Dalal D, Jain R, Tandri H, et al. Long-term efficacy of catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular dysplasia cardiomyopathy. *J Am Coll Cardiol* 2007;50:432-40.

87. Verma A, Kilicaslan F, Schweikert RA, et al. Short- and long-term success of substrate-based mapping and ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia. *Circulation* 2005;111:3209-16.

88. Wei W, Liao H, Xue Y, et al. Long-term outcomes of radio-frequency catheter ablation on ventricular tachycardias due to arrhythmogenic right ventricular cardiomyopathy: a single center experience. *PLoS One* 2017;12:e0169863.

89. Satomi K, Kurita T, Suyama K, et al. Catheter ablation of stable and unstable ventricular tachycardias in patients with arrhythmogenic right ventricular dysplasia. *J Cardiovasc Electrophysiol* 2006;17:469-76.

90. Marchlinski FE, Callans DJ, Gottlieb CD, et al. Linear ablation lesions for control of unmappable ventricular tachycardia in patients with ischemic and nonischemic cardiomyopathy. *Circulation* 2000;101:1288-96.